In September 2014, the United States Food and Drug Administration (FDA) approved the clinical use of the arithmetic products of IGFBP7 and TIMP2, known as the NephroCheck test (Astute Medical, San Diego, CA, USA) (united in (ng/mL)2/1000), to be used in ICU patients to predict the risk of developing moderate to severe AKI. Here, IGFBP7 is linked to acute kidney injury.